Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.60%0700.HK-5.61%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.20%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.49%0857.HK-1.46%UNH-10.21%1288.HK-1.06%PM-0.85%0005.HK-1.88%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.70%AUDUSD-1.54%EURAUD+1.06%AUDCHF-1.05%AUDCAD-1.01%AUDNZD-1.00%GBPAUD+0.97%GBPJPY-0.74%NZDJPY-0.72%CADJPY-0.70%EURJPY-0.68%AUDSGD-0.66%CHFJPY-0.66%AUDDKK-0.61%GBPUSD-0.56%USDCAD+0.54%NZDUSD-0.54%USDCHF+0.53%AUDNOK-0.51%EURUSD-0.50%GBPTRY+0.41%NZDMXN+0.38%USDMXN+0.33%GBPHKD+0.32%USDZAR+0.29%GBPMXN-0.28%EURZAR+0.22%USDTRY+0.21%USDTHB+0.21%USDJPY-0.18%GBPZAR+0.18%CHFNOK+0.18%USDILS+0.16%USDNOK+0.16%USDCNH-0.12%NOKJPY-0.12%CHFSEK+0.11%EURNOK+0.10%USDPLN+0.10%USDSEK+0.10%EURCNH-0.09%GBPSGD-0.09%NZDSGD+0.08%EURGBP+0.07%EURHKD-0.07%USDDKK+0.06%PLNJPY-0.06%EURSGD-0.05%NZDCHF-0.05%EURCZK+0.04%EURPLN+0.04%EURSEK+0.04%SGDJPY+0.04%GBPCAD-0.04%EURNZD+0.04%GBPCHF-0.04%USDCOP-0.04%EURCAD+0.04%EURCHF+0.03%CHFSGD+0.03%NZDCAD-0.02%CADCHF-0.02%GBPNZD-0.02%USDHKD-0.01%USDSGD+0.01%EURDKK0.00%XNGUSD-0.70%UKOIL+0.65%W1-0.55%USOIL+0.51%XAGUSD+0.50%GAGUSD+0.50%GAUUSD+0.48%XAUUSD+0.48%C1-0.41%S1-0.29%COTTON+0.24%HG1-0.10%BTCUSD-3.45%ETHUSD+57.77%USDTUSD-0.02%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.83%ZECUSDT-6.47%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.21%XLMUSD-3.67%BCHUSDT-3.36%LTCUSD+47.50%UNIUSD-2.76%SUIUSD-3.02%TONUSD+59.18%HBARUSDT-4.80%TAOUSDT-2.98%AAVEUSD-3.50%ONDOUSDT-5.26%ICPUSDT-1.91%DOTUSDT-3.76%WLDUSDT-3.57%ARBUSDT-5.15%ATOMUSDT-2.31%INJUSDT-7.31%STXUSDT-2.75%PYTHUSDT-0.66%TIAUSDT-3.37%FETUSDT-4.31%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.17%OPUSDT-2.63%IOTAUSDT-2.43%POLUSDT-1.89%WIFUSDT-2.98%AXSUSDT-2.62%EOSUSDT-4.17%IMXUSDT-3.36%FARTCOINUSDT-6.14%GALAUSDT-2.38%DYDXUSDT-2.38%ORDIUSDT-2.50%NOTUSDT+0.86%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.60%0700.HK-5.61%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.20%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.49%0857.HK-1.46%UNH-10.21%1288.HK-1.06%PM-0.85%0005.HK-1.88%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.70%AUDUSD-1.54%EURAUD+1.06%AUDCHF-1.05%AUDCAD-1.01%AUDNZD-1.00%GBPAUD+0.97%GBPJPY-0.74%NZDJPY-0.72%CADJPY-0.70%EURJPY-0.68%AUDSGD-0.66%CHFJPY-0.66%AUDDKK-0.61%GBPUSD-0.56%USDCAD+0.54%NZDUSD-0.54%USDCHF+0.53%AUDNOK-0.51%EURUSD-0.50%GBPTRY+0.41%NZDMXN+0.38%USDMXN+0.33%GBPHKD+0.32%USDZAR+0.29%GBPMXN-0.28%EURZAR+0.22%USDTRY+0.21%USDTHB+0.21%USDJPY-0.18%GBPZAR+0.18%CHFNOK+0.18%USDILS+0.16%USDNOK+0.16%USDCNH-0.12%NOKJPY-0.12%CHFSEK+0.11%EURNOK+0.10%USDPLN+0.10%USDSEK+0.10%EURCNH-0.09%GBPSGD-0.09%NZDSGD+0.08%EURGBP+0.07%EURHKD-0.07%USDDKK+0.06%PLNJPY-0.06%EURSGD-0.05%NZDCHF-0.05%EURCZK+0.04%EURPLN+0.04%EURSEK+0.04%SGDJPY+0.04%GBPCAD-0.04%EURNZD+0.04%GBPCHF-0.04%USDCOP-0.04%EURCAD+0.04%EURCHF+0.03%CHFSGD+0.03%NZDCAD-0.02%CADCHF-0.02%GBPNZD-0.02%USDHKD-0.01%USDSGD+0.01%EURDKK0.00%XNGUSD-0.70%UKOIL+0.65%W1-0.55%USOIL+0.51%XAGUSD+0.50%GAGUSD+0.50%GAUUSD+0.48%XAUUSD+0.48%C1-0.41%S1-0.29%COTTON+0.24%HG1-0.10%BTCUSD-3.45%ETHUSD+57.77%USDTUSD-0.02%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.83%ZECUSDT-6.47%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.21%XLMUSD-3.67%BCHUSDT-3.36%LTCUSD+47.50%UNIUSD-2.76%SUIUSD-3.02%TONUSD+59.18%HBARUSDT-4.80%TAOUSDT-2.98%AAVEUSD-3.50%ONDOUSDT-5.26%ICPUSDT-1.91%DOTUSDT-3.76%WLDUSDT-3.57%ARBUSDT-5.15%ATOMUSDT-2.31%INJUSDT-7.31%STXUSDT-2.75%PYTHUSDT-0.66%TIAUSDT-3.37%FETUSDT-4.31%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.17%OPUSDT-2.63%IOTAUSDT-2.43%POLUSDT-1.89%WIFUSDT-2.98%AXSUSDT-2.62%EOSUSDT-4.17%IMXUSDT-3.36%FARTCOINUSDT-6.14%GALAUSDT-2.38%DYDXUSDT-2.38%ORDIUSDT-2.50%NOTUSDT+0.86%RONINUSDT-2.92%
TT

Travere Therapeutics, Inc. (TVTX)

NASDAQ • Healthcare

$50.24
-$0.85 (-1.7%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$51.06
Day Range$49.8 - $51.4
Avg. Volume (3M)2.1M
Market Cap$4.8B
52 Week Range
$22.59$68.73

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$224.5M100%
Gross Profitminus cost of goods$221.6M99%

In plain terms: out of every $100 in revenue, Travere Therapeutics, Inc. currently loses $23.

Fundamentals & Financials

Revenue (TTM)
$651M
Net Income (TTM)
-$121.5M
EPS (TTM)
-$1.56
ROA (TTM)
-14.32%
Current Ratio
3

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-30.0%Q2 2026-$0.39
-174.8%Q3 2026-$0.37
-891.9%Q4 2026-$0.55

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Miss -891.9%

Travere Therapeutics’ third fiscal quarter of 2026 paired a revenue beat with an earnings miss when it reported results on November 2, 2026, as revenue of $224.6 million topped the $195.3 million estimate, +15%, while EPS of -$0.55 trailed the -$0.10 estimate by -$0.45. Revenue rose 36.2% to about $224.6 million, up from about $164.9 million a year ago, reflecting contributions from its marketed portfolio led by FILSPARI and Thiola-based treatments. Profitability remained negative, with operating income of roughly -$68.1 million translating to an operating margin of about -30%, and net income came in at roughly -$52.3 million versus about $25.7 million a year earlier. Despite the GAAP loss, the company generated operating cash flow of about $74.7 million during the quarter. For the next period, consensus calls for EPS of $0.45 on revenue of $234.6 million.

View full earnings history

About Travere Therapeutics, Inc.

Travere Therapeutics, Inc. is a NASDAQ-listed biotechnology company developing and commercializing therapies for rare kidney and metabolic diseases, with $490.7 million in revenue in FY2025. Its business centers on specialty medicines for small patient populations, led by FILSPARI for rare kidney disorders and Thiola-based treatments for cystinuria.

Name
Travere Therapeutics, Inc.
CEO
Eric Dube
Industry
Healthcare
Employees
497

Today's Snapshot

AI-generated

TVTX closed 1.7% below yesterday's close, in line with a weaker sector. Shares changed hands at about two-thirds of its usual level.

Trading Volume

Below 10d avg (1.2M)

830.2K

vs S&P 500 Today

Underperforming Market

-1.42%

Updated: November 18, 2026 at 21:12 UTC

Technical Indicators

1 Buy3 Neutral4 Sell
TVTX is rated a sell as momentum has turned mildly negative while trend strength remains weak, leaving limited directional conviction. The stock sits near fifty dollars and is trading under its short- and medium-term moving averages even though it remains above the 200-day average, which signals mixed longer-term support. Volatility is moderate with an average true range near five percent, and momentum indicators are soft rather than oversold, so momentum and MACD do not confirm a clear rebound. By contrast, on-balance volume shows accumulation despite price weakness, keeping the picture nuanced. Technical takeaway: Sell.
All signals
  • EMA (5 indicators)$47.44 - $54.01
    Sell
  • RSI (14)43.88
    Neutral
  • Stochastic %K (14, 3, 3)65.54
    Neutral
  • MACD Level (12, 26)-1.00
    Neutral

Peers & Related Assets

Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.